indazoles has been researched along with Cancer of the Fallopian Tube in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (66.67) | 24.3611 |
| 2020's | 4 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bhatti, A; Horton, ER; Kerliu, L; Myruski, S; Pervanas, HC; Petrosius, P; Soni, P | 1 |
| Barroilhet, LM; Brown, J; Darus, C; Duska, LR; Jelovac, D; McGuire, WP; Moore, KN; Petroni, GR; Secord, AA; Varhegyi, N | 1 |
| Dockery, L; Moore, K; Randall, LM; Rimel, BJ | 1 |
| Alvarez, N; Colombo, N; dePont Christensen, R; Gonzalez Martin, A; Heitz, F; Marqués, C; Meirovitz, M; Sanchez Lorenzo, L; Sanchez, J; Selle, F; van Gorp, T | 1 |
| Scott, LJ | 1 |
| Beijnen, JH; Gebretensae, A; Hughes, L; Kansra, V; Rosing, H; Sanghvi, M; Schellens, JHM; Tibben, MM; van Andel, L; Zhang, Z | 1 |
| Longoria, TC; Tewari, KS | 1 |
| Callahan, T; Chan, JK; Guo, W; Moore, K; Patel, MR; Secord, AA; Zhang, ZY | 1 |
| Azodi, M; Berek, JS; Chan, JK; Cloven, N; Cristea, M; DiSilvestro, P; Fleming, GF; Geller, MA; Li, Y; Luptakova, K; Matei, DE; Matulonis, UA; Miller, DS; Monk, BJ; Moore, KN; Oza, AM; Rimel, BJ; Secord, AA; Sun, K; Wahner Hendrickson, AE | 1 |
| Barrett, C; Calvert, P; Colombo, N; Crescenzo, RJ; del Campo, JM; du Bois, A; Fiane, B; Floquet, A; Friedlander, M; Herzog, TJ; Isonishi, S; Kim, JW; Meier, W; Mitrica, I; Monk, BJ; Pisano, C; Reinthaller, A; Vergote, I; Wang, K | 1 |
| Barrett, C; Berton-Rigaud, D; Chan, JK; Colombo, N; Del Campo, JM; du Bois, A; Forget, F; Friedlander, M; Harter, P; Heitz, F; Herzog, TJ; Imhof, M; Jobanputra, M; Johnson, T; King, K; Mirza, MR; O'Donnell, D; Park, SY; Shimada, M; Stinnett, S; Xu, CF; Zamagni, C | 1 |
| Friedlander, M; Hancock, KC; Hodge, JP; Lager, JJ; Ma, B; Matthys, GM; Messing, MJ; Rischin, D; Stringer, CA | 1 |
2 review(s) available for indazoles and Cancer of the Fallopian Tube
| Article | Year |
|---|---|
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Topics: Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival | 2020 |
Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life | 2018 |
8 trial(s) available for indazoles and Cancer of the Fallopian Tube
| Article | Year |
|---|---|
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Indazoles; Middle Aged; Peritoneal Neoplasms; Pyrimidines; Sulfonamides | 2020 |
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Peritoneal Neoplasms; Piperidines; Platinum; Progression-Free Survival; Time Factors | 2021 |
Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Breast Neoplasms; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Radioactive Tracers; Tandem Mass Spectrometry | 2018 |
Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Topics: Aged; Carcinoma, Ovarian Epithelial; Cardiotoxicity; Double-Blind Method; Electrocardiography; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Long QT Syndrome; Middle Aged; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors | 2019 |
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Topics: Adolescent; Adult; Aged; BRCA1 Protein; BRCA2 Protein; Canada; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Middle Aged; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Time Factors; United States; Young Adult | 2019 |
Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.
Topics: Angiogenesis Inhibitors; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Double-Blind Method; Endpoint Determination; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrimidines; Sulfonamides | 2015 |
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Genome-Wide Association Study; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrimidines; Sulfonamides; White People; Young Adult | 2016 |
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; CA-125 Antigen; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrimidines; Sulfonamides; Survival Rate | 2010 |
2 other study(ies) available for indazoles and Cancer of the Fallopian Tube
| Article | Year |
|---|---|
Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer.
Topics: Fallopian Tube Neoplasms; Female; Humans; Indazoles; Molecular Targeted Therapy; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Treatment Outcome | 2020 |
Niraparib: First Global Approval.
Topics: Adult; Carcinoma, Ovarian Epithelial; Double-Blind Method; Drug Approval; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2017 |